| Literature DB >> 29678874 |
Alvaro Teijeira1,2, Sara Labiano3, Saray Garasa3, Iñaki Etxeberria3, Eva Santamaría3,4, Ana Rouzaut3,2, Michel Enamorado5, Arantza Azpilikueta3,2, Susana Inoges3, Elixabet Bolaños3,2, Maria Angela Aznar3, Alfonso R Sánchez-Paulete3,2, David Sancho5, Ignacio Melero1,2.
Abstract
T and NK lymphocytes express CD137 (4-1BB), a costimulatory receptor of the TNFR family whose function is exploitable for cancer immunotherapy. Mitochondria regulate the function and survival of T lymphocytes. Herein, we show that CD137 costimulation provided by agonist mAb and CD137L (4-1BBL) induced mitochondria enlargement that resulted in enhanced mitochondrial mass and transmembrane potential in human and mouse CD8+ T cells. Such mitochondrial changes increased T-cell respiratory capacities and were critically dependent on mitochondrial fusion protein OPA-1 expression. Mass and function of mitochondria in tumor-reactive CD8+ T cells from cancer-bearing mice were invigorated by agonist mAb to CD137, whereas mitochondrial baseline mass and function were depressed in CD137-deficient tumor reactive T cells. Tumor rejection induced by the synergistic combination of adoptive T-cell therapy and agonistic anti-CD137 was critically dependent on OPA-1 expression in transferred CD8+ T cells. Moreover, stimulation of CD137 with CD137 mAb in short-term cultures of human tumor-infiltrating lymphocytes led to mitochondria enlargement and increased transmembrane potential. Collectively, these data point to a critical link between mitochondrial morphology and function and enhanced antitumor effector activity upon CD137 costimulation of T cells. Cancer Immunol Res; 6(7); 798-811. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29678874 DOI: 10.1158/2326-6066.CIR-17-0767
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151